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Abstract
Hyperlactatemia is a strong predictor of mortality in diverse populations of critically ill patients. In this article, we will give an
overview of how lactate is used in the intensive care unit. We describe the use of lactate as a predictor of outcome, as a marker to
initiate therapy and to monitor adequacy of initiated treatments.
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Introduction
Hyperlactatemia has been associated with morbidity and mor-
tality since the first description in 1843 by Scherer.1 The use of
lactate as a prognostic tool was first suggested by Broder and
Weil more than 120 years later.2 They observed that a lactate
level 4 mmol/L was associated with a 50% mortality in
patients with shock.2 More than 30 years later, the mortality
associated with this lactate level is similar.3 Nowadays, lactate
is easily available and routinely measured in most critically ill
patients in the intensive care unit (ICU) and emergency depart-
ment (ED). In this article, we will give an overview of how
lactate is used in the ICU. We discuss the use of lactate as a
predictor of outcome, as a marker to initiate therapy and to
monitor adequacy of initiated treatments.
The Pathophysiology of Lactate
To fully understand the mechanisms involved in the 3 topics
being discussed, it is important to have knowledge on the meta-
bolism of lactate. Lactate exists in the body as 2 stereoisomers:
L-lactate and D-lactate. In humans, L-lactate is the dominant
isomer that is synthesized and utilized. Accumulation of this
isomer represents the vast majority of clinical cases of hyper-
lactatemia.4 Lactate is produced in the metabolism of glucose
(Figure 1). Glycolysis converts glucose into 2 molecules of
pyruvate with the net gain of 2 adenosine triphosphates (ATPs).
More ATP can be generated in the oxidative part of the glucose
metabolism: by entrance of pyruvate to the tricarboxylic acid
cycle (TCA or Krebs cycle) and the oxidative phosphorylation
in several organs like the liver, kidneys, and muscles. Pyruvate
is the molecule that links glycolysis to TCA and oxidative
phosphorylation. Pyruvate can be converted to lactate by a
reversible oxido-reduction reaction catalyzed by the enzyme
lactate dehydrogenase in the cytosol (Figure 1). Under normal
circumstances, TCA and oxidative phosphorylation provide the
major amount of ATP for cellular function. The rate of glyco-
lysis is faster than the TCA and oxidative phosphorylation, as a
consequence glycolysis can briefly provide far more ATP in
situations of cellular stress. Excess pyruvate will rapidly accu-
mulate and is converted into lactate. In case large amounts of
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Figure 1. Nonoxidative and oxidative glucose metabolism.
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energy are rapidly required, for example, cellular stress, lactate
serves as a critical buffer that allows glycolysis to accelerate.5
Normally the lactate:pyruvate ratio is 10:1; however, when the
cellular redox state changes because of anaerobic metabolism
(ie, when the NADH:NADþ ratio increases), this ratio rises.4
Approximately 20 mmol of lactate per kilogram of body
weight is generated each day, mostly in the muscles and skin.4,6
Production of lactate by glycolysis is accompanied by the pro-
duction of protons from the ATP degradation: glucose þ 2
(ADP þ inorganic phosphate) ! 2 lactate þ 2Hþ þ 2 ATP.
As lactate consumption removes protons, the overall effect on
acid–base balance is limited.4
Lactate produced by the muscles in the conversion of glyco-
gen to glucose in anaerobic glycolysis is converted back to
glycogen and glucose by the liver in gluconeogenesis. This
process is called the Cori cycle and is especially important
during intensive exercise.4
Normally the production and consumption of lactate are
balanced. When production exceeds consumption, hyperlacta-
temia is the result. In combination with the accompanied pro-
duction of protons, hyperlactatemia potentially results in
acidosis. In clinical practice, increasing lactate levels above
5 mmol/L are frequently associated with worsening acidosis.7
Traditionally, 2 types of hyperlactatemia have been clinically
used: hypoxic and nonhypoxic causes. However, both types
usually coexist. Hypoxic-related causes are a result of inade-
quate microvascular oxygen supply. Both experimental and
clinical studies have shown that a reduction in global oxygen
delivery will ultimately result in a decrease in oxygen con-
sumption. When oxygen demand remains stable, this decrease
in oxygen consumption hallmarks the occurrence of tissue
hypoxia and is associated with a sharp increase in lactate lev-
els.8,9 Microcirculatory dysfunction resulting in changes in the
microcirculation is also thought to play an important role. Het-
erogeneity of microcirculatory blood flow, varying from tissue
zones receiving adequate perfusion through capillaries with
continuous flow to zones without microvascular perfusion,
results in impaired oxygen delivery at cellular level.10-12
In nonhypoxic causes of hyperlactatemia, increased lactate
levels are the result of increased glycolysis depending on other
factors than hypoxia as a result of metabolic changes, impaired
clearance of lactate, or toxic causes. There are multiple meta-
bolic causes for hyperlactatemia, for example, a cytokine-
dependent increase of cellular glucose uptake in inflammatory
states, mitochondrial dysfunction, drugs that impair oxidative
phosphorylation, and stimulation by epinephrine.4 Experimen-
tal data suggest that epinephrine induces hyperlactatemia by
binding to muscle adrenergic b2-receptors and raising AMP
production,13 leading in turn to the concurrent stimulation of both
Naþ-Kþ-ATPase activity and glycogenolysis.14 Activation of
Naþ-Kþ-ATPase generates ADP and liberates Hþ, thereby
raising phosphofructokinase activity, accelerating aerobic gly-
colysis, and thus increasing lactate concentration and decreas-
ing pH.
Impaired lactate clearance may contribute to hyperlactate-
mia, although studies show conflicting results. Levraut et al
demonstrated that in patients with sepsis, despite hemodyna-
mically stable and normal liver function, lactate clearance can
be reduced possibly through inhibition of pyruvate dehydro-
genase.15 On the other hand, Revelly et al showed that hyper-
lactatemia was mainly related to increased production in
patients with sepsis, septic shock, or cardiogenic shock. Lactate
clearance in these patients was comparable to healthy
patients.16 In a recent experimental study, Tapia et al showed
that clearance of lactate by the liver was almost abolished
during septic shock conditions.17
Finally, multiple drugs influence lactate levels. Metformin
can cause hyperlactatemia due to interference with oxidative
phosphorylation as it suppresses hepatic gluconeogenesis.
Hyperlactatemia is usually seen in high metformin plasma
levels. b2-agonists can cause hyperlactatemia by stimulating
aerobic glycolysis. Moreover, nucleoside reverse transcrip-
tase inhibitors interfere with oxidative phosphorylation
potentially resulting in hyperlactatemia.4,8 As a consequence,
hyperlactatemia can be present in all different types of
diseases and can be a helpful measurement in the diagnostic
process (Table 1).
Table 1. Potential Use of Lactate as a Diagnostic Test.
Situation Pathophysiology
Grand mal seizures Excessive muscle activity resulting in increased
anaerobic glycolysis. Hyperlactatemia is
transient and should resolve quickly after
cessation of the seizures. Sustained
hyperlactatemia after seizure suggests
another or concomitant origin.
Lymphoma The Warburg effect: hyperlactatemia as a result
of aerobic production of lactate as a source
of energy.
HIV medication Nucleoside reverse transcriptase inhibitors
interfere with oxidative phosphorylation.
Metformin Hyperlactatemia is usually seen in high
metformin plasma levels. Metformin
interferes with oxidative phosphorylation as
it suppresses hepatic gluconeogenesis.
Metabolic diseases Rare inborn errors of metabolism can cause
dysfunction in a variety of metabolic steps
including gluconeogenesis, pyruvate
dehydrogenase, the tricarboxylic acid cycle,
and the respiratory chain.
Asthma
exacerbation
Increased muscle activity resulting in augmented
anaerobic glycolysis and (excessive) use of
b2-sympathicomimetics resulting in
stimulation of aerobic glycolysis.
Thiamin deficiency Impairment of pyruvate dehydrogenase activity.
Liver dysfunction The liver accounts for up to 70% of whole-body
lactate clearance. Chronic liver diseases
rarely generate hyperlactatemia but
augments it in case of sepsis. Hyperlactatemia
is, however, common in acute liver failure.
Carbon monoxide
poisoning
Decreased oxygen delivery to the tissues and
interference with oxidative phosphorylation.
Severe anemia Decreased oxygen delivery to the tissues.
Pheochromocytoma Induced b2-adrenoceptor stimulation due to
high levels of catecholamines.
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In summary, hyperlactatemia represents an imbalance
between increased production in the presence or absence of
tissue hypoxia and changes in clearance.
Lactate as Predictor of Outcome
The prognostic value of multiple types of lactate levels or
calculations from lactate levels has been investigated in diverse
groups of critically ill patients, for example, initial lactate lev-
els at presentation, duration of hyperlactatemia, the area under
the receiver operating characteristic (AUROC) curve, and lac-
tate clearance (the initial lactate—subsequent lactate/initial
lactate 100%). The use of this former definition is confusing,
as lactate clearance should be defined as the metabolism of
lactate.18 Therefore, we recommend to use the term change
or decrease in lactate, since it reflects the end result of both
lactate production and consumption.
The predictive value of the initial lactate level has been
investigated in diverse populations, for example, in septic
patients,19-23general ICU patients,24,25 critically ill patients,26
patients with a pulmonary embolism27 and patients admitted to
the ICU after high-risk surgery.28 In all these groups of
patients, the initial lactate level is a predictor of outcome.
Studies in trauma patients show, however, mixed results.29-32
In a heterogeneous ICU population, the duration of hyper-
lactatemia is related to sequential organ failure assessment
scores and its organ subscores as an indicator of organ fail-
ure/dysfunction. The respiratory and coagulation subscores
were most strongly associated with hyperlactatemia. This rela-
tionship was stronger during the early phase of ICU stay.25 In
patients with septic shock at the ICU,33,34 trauma patients,35
and a mixed population of ICU patients,36 decreasing lactate
levels or normalization of lactate are related with better out-
comes. In contrast, in a heterogeneous population of patients
with different causes of low-oxygen transport (eg, hemorrhage,
low cardiac output, low hemoglobin level, or oxygen satura-
tion), only the lactate levels at admission, but not the reduction
over time, predicted mortality.33
The AUROC curve gives information on the accuracy of a
test. The accuracy of lactate to predict mortality in the ED and
ICU varies from moderate (0.53) to excellent (0.99). Shapiro
et al found that lactate at admission in patients with suspected
infections had an AUROC curve of 0.67.22 Kaplan and Kellum
showed the initial lactate level to have an AUROC curve of
0.99 in trauma patients.32 In the ICU, the AUROC curve varied
from 0.53 in hemodynamically unstable critically ill patients37
and 0.58 in hemodynamically stable patients after high-risk
surgery28 to 0.86 in patients after hepatectomy.38 In these het-
erogeneous groups of critically ill patients, measured lactate
shows varied prognostic performance.
In patients with a cardiac arrest, the change in lactate levels
is related to mortality. Higher decreases in lactate at 6 and
12 hours are associated with decreased mortality (both 24 hours
and in-hospital mortality).39 In patients who survived the first
48 hours after cardiac arrest, lactate at 48 hours is an indepen-
dent predictor of mortality and unfavorable neurologic
outcome. Persistent hyperlactatemia over 48 hours predicted
a poor prognosis.40 Also patients with sepsis having a success-
ful decrease in lactate (defined as a decrease in lactate 10%)
show higher survival rates compared with patients in whom
lactate levels decreased less than 10%.41,42 Puskarich et al iden-
tified early lactate normalization (defined as a decrease in lac-
tate to 2.0 mmol/L) during the first 6 hours of resuscitation as
the strongest independent predictor of survival and superior to
other measures of lactate kinetics.23 Nguyen et al showed that
in patients with severe sepsis or septic shock, there was a
+11% decreased likelihood of mortality for each 10%
decrease in lactate.42
In a recent meta-analysis of 96 clinical studies, Vincent et al
showed that a decrease in lactate levels was associated with
improved outcome in almost all subgroups of critically ill
patients,43 thereby acknowledging the universal predictive
power of lactate levels. Despite this long-standing and strong
predictive power of increased lactate levels to predict increased
morbidity and mortality, no studies have been published on the
clinical use of this characteristic. In a study by Jansen et al on
the use of lactate to guide initial resuscitation, even patients
with a 100% predicted mortality based on admission lactate
levels were admitted.3 Up until now, lactate levels and the
association with mortality have only been used to advocate
aggressive treatment,44,45 hereby ignoring the complex origin
of increased lactate levels in critically ill patients.46
In summary, despite its long-standing predictive power, it is
still unclear how lactate levels influence clinical decision-
making with regard to admission policies or end-of-life
decisions.
Lactate as a Marker to Initiate Therapy
As mentioned above, increased lactate levels have been advo-
cated to initiate treatment in many clinical conditions. As vital
signs can be misleading in the identification of patients with
circulatory dysfunction, as for example, in early phases of
shock,47 increased lactate levels have been used to characterize
patients with impaired tissue perfusion and oxygenation.48,49
Indeed, when one relies on vital signs only to identify patients
with inadequate perfusion, a substantial number of patients
with prognostically important hypoperfusion may remain
undetected.50,51 This has been demonstrated for patients with
cardiogenic shock,51 trauma patients,50 hemodynamic stable
patients in the ICU after high-risk surgery,28 and critically ill
patients in the ED.52 Only when compensatory mechanisms
fail, vital signs will change. Delayed identification of patients
with compensated shock may lead to delayed or inadequate
resuscitation. Ideally, disease severity is already assessed
before presentation at the ED. Several studies demonstrated the
potential use of prehospital lactate sampling as a warning sig-
nal to initiate treatment. Prehospital lactate was significantly
associated with emergent operations and multiple organ dys-
function in trauma patients.29 Compared to systolic blood pres-
sure, lactate was a better predictor for the need of significant
packed red blood cell transfusion in trauma patients with a
Vink and Bakker 3
relatively normal systolic blood pressure (90-110 mm Hg) at
presentation.53 Moreover, van Beest et al showed that signifi-
cantly more patients with shock and high (>4 mmol/L) lactate
levels needed intubation compared to patients with shock and
low (<4 mmol/L) lactate levels (1.4% vs 24.6%).54
However, very few studies have reported on the efficacy of
actually using lactate levels to guide treatment. In cardiac sur-
gery patients, Polonen et al studied the effect of improving
hemodynamics whenever mixed venous oxygenation or lactate
levels were or became abnormal in a randomized study.55
Although there was no effect on mortality, the use of this pro-
tocol to initiate treatment was associated with a decrease in
organ failure.55 In a mixed group of patients with circulatory
failure (defined as a lactate level 3.0 mmol/L), Jansen et al
investigated lactate-guided treatment.3 Patients were rando-
mized to either treatment guided by lactate levels with the
objective to decrease lactate by20% per 2 hours for the initial
8 hours of ICU stay or standard care without any information
on lactate levels except for the initial lactate levels used to
randomize the patient. The lactate group received more fluids
and vasodilators in the 8-hour study period but less fluids in
the follow-up period, a finding consistent with the landmark
study on early goal-directed therapy of Rivers et al56 Surpris-
ingly, there were no differences in lactate levels at any time
point during the study period between both groups. This
underscores the complex etiology of lactate levels in critically
ill patients. Moreover, the effect of the Rivers study56 on
initial resuscitation to correct tissue hypoperfusion obviously
affected therapeutic measures in the control group. Never-
theless, the lactate group had a significant lower morbidity and
hospital mortality.3 Therefore, it seems that lactate in addition
to its use in initiating treatment may serve as a warning signal
to the treatment team to rethink diagnostic and therapeutic
options.
Treatment of hyperlactatemia should relate to its pathophy-
siology. In case of impaired tissue perfusion/oxygenation, ther-
apeutic measures differ greatly when compared to intoxication,
as for instance in metformin intoxication, or when increased
lactate levels are the result of decreased clearance or increased
aerobic lactate production. Given the significant effect of inad-
equate tissue perfusion on outcome, increased lactate levels
should first be evaluated in this context. When the likelihood
of tissue hypoperfusion is real, increased lactate levels should
be seen as an indication to improve tissue perfusion. Crystal-
loid and colloid solutions are both effective in restoring perfu-
sion in case of hypovolemia and sepsis.57 Vasopressors and
inotropic agents should be administered as needed.49 It is
important to take into account that the use of epinephrine is
associated with increases in lactate not related to tissue hypo-
perfusion but increased glycolysis, glycogenolysis, and stimu-
lation of the Na-K-pump.58,59 The balance between oxygen
delivery and oxygen demand can be improved by ameliorating
oxygen delivery by packed red blood cell transfusions when
indicated, augmenting cardiac output, increasing SaO2 by intu-
bation when necessary and improving microcirculatory perfu-
sion by enhancing regional blood flow with, for example,
dobutamine, enoximone, or nitroglycerin or by decreasing oxy-
gen demand by mechanical ventilation.60,61
A meta-analysis62 and several other studies have now shown
the efficacy of using increased lactate levels to initiate specific
treatment aimed to improve tissue perfusion/oxygenation in
critically ill patients. However, given the complex origin of
increased lactate levels, this probably refers to only the first
hours of ICU resuscitation.63
In summary, increased lactate levels have a prominent place
in the early goal-directed therapy in critically ill patients,
whereas the effects later on during ICU admission are
unknown.
Lactate to Monitor Adequacy of Initiated
Therapies
The Surviving Sepsis Campaign recommends the use of central
venous pressure (CVP), mean arterial pressure (MAP), urine
output, and central venous oxygen saturation (ScvO2) as resus-
citation goals. Targeting resuscitation to normalize lactate in
patients with elevated lactate levels is recommended.49 Jones
et al compared lactate decrease (target: lactate decrease 
10%) with ScvO2 improvement (target: ScvO2 70%) as goals
for sepsis resuscitation in a noninferiority trial including
patients with severe sepsis and evidence of hypoperfusion or
septic shock admitted to the ED. Patients were randomly
assigned to one of the protocols for a maximum of 6 hours.
Administered treatments did not differ between the groups, and
there were no differences in in-hospital mortality.64 This sug-
gests that lactate measurements perform as good as ScvO2
measurements. However, this study has some severe limita-
tions to draw such conclusions. At first, it is questionable
whether a 10% reduction in lactate in 6 hours represents effec-
tive resuscitation. Moreover, ScvO2 measurements can poten-
tially give insight into the pathogenesis of hyperlactatemia by
differentiating between hypoxic and nonhypoxic causes of
hyperlactatemia. Additionally, only 10% of the patients
received either dobutamine or packed red blood cell transfu-
sions. Finally, fluids and vasopressors were guided by CVP
and MAP in both groups. As a result, the potential difference
in protocol actions directly attributable to either lactate or
ScvO2 measurements was very small. Therefore, it seems
unlikely that a change in this resuscitation target could
increase mortality by 10%, the noninferiority margin selected
for the trial.5
In a substudy of the Jones study, Puskarich et al demon-
strated in patients with septic shock undergoing early resusci-
tation in the ED that failure to achieve the targeted lactate
decrease (lactate <2 mmol/L within 6 hours) was associated
with worse prognosis than failure to achieve the ScvO2 goal
(ScvO2  70%).65
Hernandez et al investigated the time course of lactate
normalization during successful resuscitation.63 They sug-
gested that the normalization of lactate consists of 2 phases:
an early rapid response (flow-responsive phase) and a later
slower recovery trend (potentially explained by non-flow-
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dependent mechanisms). Interestingly, pure flow-dependent
flow-responsive variables such as ScvO2, capillary refill time,
and central venous–arterial pCO2 showed a faster normaliza-
tion rate than lactate.63 Therefore, the use of serial lactate levels
as a clinical target is limited by the slow changes in lactate
levels. They should rather be seen as regular “checks” to make
sure the management is appropriate. Quick normalization of
lactate levels as a resuscitation goal can potentially have neg-
ative effects like fluid overload. Therefore, it seems not ade-
quate to use lactate levels as the only goal of resuscitation.
Moreover, a substantial proportion of patients with septic shock
have lactate levels within the normal range. On the other side,
also in critically ill patients admitted to the ICU with relative
hyperlactatemia (lactate levels 0.0-2.0 mmol/L), high normal
levels are independently associated with increased hospital
mortality.66 The authors suggest that the reference values
require adjustment since patients with lactate concentrations
>0.75 mmol/L are already at a higher risk of dying.66
In summary, a decrease in lactate levels following initiation
of therapy is universally a good sign. An increase in lactate
levels or even no change should warrant the treatment team to
rethink the diagnosis and rationale of current treatment. Lactate
levels should also be monitored when they are initially normal,
to identify early a deterioration.
Conclusion
The pathophysiology of hyperlactatemia is complex with
hypoxic and nonhypoxic mechanisms, often coinciding.
Hyperlactatemia is a strong predictor of mortality in diverse
populations of critically ill patients. It is, however, still unclear
how lactate levels influence clinical decision-making with
regard to admission policies or end-of-life decisions. Increased
lactate levels have a prominent place in the early treatment of
critically ill patients, whereas the effects later on during ICU
admission are unknown. A decrease in lactate levels following
initiation of therapy is universally a good sign. An increase in
lactate levels or even no change should warrant the treatment
team to rethink the diagnosis and rationale of current treatment.
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